CPB
40
3
HCA
48
2
ZTS
47
-9
UPS
61
-3
NKE
39
-3
COP
47
2
LEN
57
-4
ETR
72
3
SWK
67
-4
CVS
52
-6
CVX
46
8
KO
47
-2
PLD
56
-5
SJM
45
9
COST
66
3
ADT
50
2
EXPD
48
-5
NAVI
52
-3
HIG
75
4
MHK
50
-5
CPB
40
3
HCA
48
2
ZTS
47
-9
UPS
61
-3
NKE
39
-3
COP
47
2
LEN
57
-4
ETR
72
3
SWK
67
-4
CVS
52
-6
CVX
46
8
KO
47
-2
PLD
56
-5
SJM
45
9
COST
66
3
ADT
50
2
EXPD
48
-5
NAVI
52
-3
HIG
75
4
MHK
50
-5
Financhill
Back

Aquestive Therapeutics 10K Form

Sell
50

AQST
Aquestive Therapeutics

Last Price:
4.89
Seasonality Move:
-18.65%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AQST News And Ratings

See the #1 stock for the next 7 days that we like better than AQST

AQST Financial Statistics

Sales & Book Value

Annual Sales: $50.58M
Cash Flow: $-11.96M
Price / Cash Flow: 0
Annual Sales: $-0.50
Price / Book: 0

Profitability

EPS (TTM): -0.46410
Net Income (TTM): $-35.19M
Gross Margin: $29.75M
Return on Equity: 0%
Return on Assets: -37.13%

Aquestive Therapeutics Earnings Forecast

Key Aquestive Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 8 years for AQST is 58.82%.
  • The Selling, General & Administrative Expenses for AQST have been equal to 62.77% of Gross Profit Margin.
  • The Research & Development expenses have been 25.91% of Revenue.
  • The Interest Expense is -94.82% of Operating Income.
  • The Net Earning history of AQST is -15.56% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 4 years.

Aquestive Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AQST
CUSIP: 03843E
Website: aquestive.com

Debt

Debt-to-Equity Ratio: -0.69
Current Ratio: 6.37
Quick Ratio: 5.78

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AQST Technical Analysis vs Fundamental Analysis

Sell
50
Aquestive Therapeutics (AQST) is a Sell

Is Aquestive Therapeutics a Buy or a Sell?